Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a once-weekly injection. It’s administered with a tiny needle that punctures ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a once-weekly injection. It's administered with a tiny needle that punctures ...

Semaglutide is the active ingredient in certain brand-name medications prescribed for obesity, type 2 diabetes, and more. Semaglutide belongs to the glucagon-like peptide-1 (GLP-1) receptor agonist ...

Semaglutide is an injectable drug formulated for the treatment of type 2 diabetes, but it’s since become increasingly popular ...

Semaglutide is a drug used for type 2 diabetes, weight loss, and more. Oral tablets and injections are both effective ways to take semaglutide. Oral tablets do not require the use of needles, but you ...

Some Canadian pharmacists are already stocking their shelves with generic versions of semaglutide, more commonly known by the brand name Ozempic. But will these generics be just as good, and how much ...

Canada is the first G7 country to authorize generic semaglutide. There are now seven other submissions currently under review for generic semaglutide by different companies.

Weight loss drugs such as Ozempic, Mounjaro and Wegovy have found their way firmly into the British vernacular over the last ...

WESTON, Fla., April 10, 2026 /PRNewswire/ - Apotex Corp. today announced it has received the first U.S. Food and Drug Administration (FDA) Tentative Approval for its Abbreviated New Drug Application ...

Semaglutide is available as the following brand-name medications: Ozempic, Wegovy, and Rybelsus. How a medication is best stored depends on the form of the drug. Injection forms of these drugs need to ...

Zydus Lifesciences Ltd. and Torrent Pharmaceuticals Ltd. on Wednesday announced a co-marketing partnership to bring semaglutide injection products to Indian markets. The firms have inked a licensing ...